CerTest Biotec expects a turnover of €100 million in 2020 thanks to PCR

Spanish companies are also fighting the COVID-19. CerTest Biotec, a company that manufactures products for in vitro diagnosis of infectious diseases, has multiplied by five its productive capacity of PCR test for the detection of coronavirus. The Aragonese company has gone from manufacturing 30,000 PCRs to 150,000 PCRs per day. CerTest Biotec has increased its turnover due to the COVID-19, as explained by the CEO and founding partner of the company, Oscar Landeta. 

The company expects to have a turnover of $117 million (€100 million) in 2020, while its turnover was $20.5 million (€17.5 million) in 2019. The Aragonese company, with headquarters in San Mateo de Gállego (Zaragoza), has received a subsidy of $585,000 (€500,000) from the Center for the Development of Industrial Technology (Cdti), belonging to the Ministry of Science and Innovation. The project consists of increasing the productive capacity of PCR test for the detection of coronavirus. 

Find out more details about the biotech company CerTest Biotec and how the coronavirus pandemic has boosted its business, with the Born2Invest mobile app. Download our companion app for free and find the latest financial headlines from around the world, from the latest breakthrough in the biotech sector to market trends and companies worth keeping a close eye on.

CerTest Biotec has multiplied by five its production capacity of diagnostic tests of Covid-19, up to 150,000 PCR per day 

Landeta said that “CerTest Biotec has an important production capacity, but everything was overflowed with the pandemic due to the increase in demand.” 

The company sought to increase production capacity with the investment of Cdti, which it finally achieved. The biotech company has invested more than (€100,000) in adapting the installation and hiring workers to increase production. CerTest Biotec has increased its staff by forty people, up to 190 workers. The company has also invested in the purchase of equipment and material to increase the production of PCR tests.

Landeta recognized that the demand for testing has decreased somewhat, but it is still relevant. The Aragonese company manufactures several products to diagnose COVID-19 and has recently launched a multiple test to detect coronavirus, flu and other infectious diseases to bias patients suffering from similar symptoms. 

The products manufactured by CerTest Biotec are sold in over 130 countries, in and outside the European Union

CerTest Biotec has hired forty workers and currently has 190 employees CerTest Biotec was founded in 2002 by Landeta and Carlos Genzor, the current technical director. The majority of the company’s ownership remains in the hands of the founders. The company distributes its products to more than 130 countries. 

CerTest Biotec sells 50% of its production outside the European Union (EU), 30% to European states and the remaining 20% in Spain. The company has a built up area of more than 7,000 square meters. The facility is divided into laboratories, where the research and development, production and quality control units are located, the production and conditioning area, warehouses and offices.

CerTest Biotec is just one of the many biotech companies that have developed since the outburst of the coronavirus pandemic. Investors are keeping their eyes on biotech stocks and invest huge amounts of money in them.

__

(Featured image by fernandozhiminaicela via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.